Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DO ATYPICAL ANTIPSYCHOTIC MEDICATIONS FAVORABLY ALTER THE LONG-TERM COURSE OF SCHIZOPHRENIA
Autore:
DEQUARDO JR; TANDON R;
Indirizzi:
UNIV MICHIGAN,CTR MED,SCHIZOPHRENIA PROGRAM,UH-9C-9150,1500 E MED CTRDR ANN ARBOR MI 48109
Titolo Testata:
Journal of Psychiatric Research
fascicolo: 3-4, volume: 32, anno: 1998,
pagine: 229 - 242
SICI:
0022-3956(1998)32:3-4<229:DAAMFA>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; CAUDATE NUCLEI VOLUMES; QUALITY-OF-LIFE; DOUBLE-BLIND; NEGATIVE SYMPTOMS; MAINTENANCE TREATMENT; CLOZAPINE TREATMENT; TARDIVE-DYSKINESIA; COST-EFFECTIVENESS; PSYCHIATRIC-SYMPTOMS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
111
Recensione:
Indirizzi per estratti:
Citazione:
J.R. Dequardo e R. Tandon, "DO ATYPICAL ANTIPSYCHOTIC MEDICATIONS FAVORABLY ALTER THE LONG-TERM COURSE OF SCHIZOPHRENIA", Journal of Psychiatric Research, 32(3-4), 1998, pp. 229-242

Abstract

Schizophrenia is characterized by the greatest degree of clinical deterioration in the first decade following onset of psychosis; in fact, deterioration begins even prior to the onset of frank psychotic symptomotology. While somewhat controversial, it appears that effective early antipsychotic treatment might limit the extent of such deterioration. The newer, atypical antipsychotics such as clozapine, risperidone, olanzapine and quetiapine appear to have antipsychotic efficacy at least equal to the traditional neuroleptics, but with a much more favorable side effect profile. Clozapine is also effective in tree ting neuroleptic-refractory schizophrenic patients. Data suggest that in comparison to conventional agents, treatment with atypical antipsychotics may be associated with a more benign course of schizophrenic illness. Whether these atypical antipsychotics are associated with greater efficacyin limiting clinical deterioration in schizophrenic illness than traditional neuroleptics is, however, unclear. The following questions will be addressed in this paper: (i) Do atypical antipsychotics differ from traditional neuroleptics in modifying the natural course of symptomatology in schizophrenic illness? (ii) Do atypical antipsychotics differ from typical neuroleptics in modifying the natural course of neurobiological and cognitive abnormalities in schizophrenic illness? (iii) Do atypical antipsychotics differ from typical neuroleptics in modifying the natural course of psychosocial dysfunction in schizophrenic illness? (iv) Are there differences between typical and atypical antipsychotics with regard to their effects on the cost of care and resource utilization? The implications of the answers to these questions for thelong-term treatment of schizophrenia will be discussed. (C) 1998 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 17:46:58